Eniola's strongest angle is: she is a Lagos-based independent researcher who identified that Nigeria's tramadol and opioid misuse crisis is being mismanaged because African clinicians and institutions lack affordable, open-source preclinical tools to screen addiction liability without wet labs — so she built them. IMPRINT (addiction-liability screening), TOPOLOGIX (drug-protein interaction), and GATE (neural-stimulation safety) are open-access platforms that let African institutions perform drug-safety evaluations that previously required expensive Western lab infrastructure. Her CCT model, validated with ODE/MCMC rather than wet-lab experiments, embodies resource-constrained innovation. The leadership narrative must centre ZYCO as an institution she is building to close Africa's computational pharmacology gap, framing herself as a founder-leader who translates cutting-edge science into democratised, locally deployable tools — not as a researcher seeking recognition. The 'values' angle should emphasise equity of access to drug-safety knowledge: that African populations deserve addiction-prevention science that is designed for, not merely adapted to, their context. Her Harvard/Princeton/Michigan collaborators should appear as validation of the work's quality, not as the centrepiece.